- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02666404
Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock (VoluKid)
Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock: Evaluating the Combination of Intraabdominal Pressure and Renal Resistive Index With Hemodynamic Parameters for Guidance of Shock Therapy - A Multicenter International Clinical Trial
Study Overview
Detailed Description
Background and Rationale, clinical evidence to date:
All forms of shock and especially septic shock, in which tissue metabolic demands are not fulfilled by blood supply, are main causes of morbidity and mortality worldwide and develops in one third of the patients admitted to the ICU. Not only is this high incidence alarming, the uncertainty about the undeceiving parameters for guidance of fluid resuscitation to not only avoid acute kidney injury and renal replacement therapy but also the consequences of fluid overload, such as interstitial pulmonary edema, underline the importance of further research within this field. This is why the investigators would like to contribute to the establishment of new parameters for the guidance of shock therapy focusing on the first 72 hours, amending the currently used parameters (i.e. cardiac output, heart rate, blood pressure, central venous pressure) with new measurements, including assessment of total body water, renal vascular resistance (renal resistive index (RRI)) and microcirculatory blood flow.
Although the application of intravenous crystalloid fluids, red blood cell concentrates in anemia, and catecholamines or inotropes are the mainstay of shock therapy, no clear endpoints for the fluid resuscitation or the hemodynamic endpoints for catecholamine therapy have been established so far. Static parameters such as central venous or arterial pressure, cardiac output, or plasma lactate failed in the guidance of the amount of fluid administered. The administration of intravenous fluids in response to so-called dynamic tests, such as stroke volume variation in response to fluid bolus administration, also did not show an influence on organ dysfunction and mortality due to shock. Acute kidney injury (AKI) is the most frequent organ dysfunction in patients in shock. Despite a more aggressive early fluid resuscitation and correction of arterial blood pressure, the incidence of AKI does not seem to decrease. One possible reason is that the excessive amount of fluid administered to these patients for hemodynamic stabilization and maintenance of urinary output harm kidney function. Indeed, a correlation between total amount of fluid administered, high central venous pressure, organ dysfunction, and mortality has been shown in patients with severe sepsis and septic shock. Established static and dynamic hemodynamic parameters are not influenced by the severity of capillary leakage and microcirculatory impairment due to inflammation-induced injury in capillaries. The relatively low perfusion pressure together with interstitial edema, microcirculatory injury, and a high outflow pressure may harm renal function by a decreased glomerular urine excretion. Intraabdominal pressure, total body water, and central venous pressure together with the renal resistive index may be additional measurements to reduce the rate of acute kidney injury and to guide fluid therapy in shock.
The goal of the present study is to refine fluid resuscitation endpoints with new measurements to administer the optimal amount of fluid with the smallest possible adverse effects. Complexity of therapy in severe sepsis and septic shock as well as in other shock states was the topic of numerous studies showing no benefit of advanced macro-circulatory parameters for guidance of fluid resuscitation in shock. If the chosen measurements are unable to establish new endpoints for guidance in shock therapy, the investigators' research might be expanded to the evaluation of future therapies, such as biomarkers or stem cells. After establishment of more regional resuscitation endpoints, the investigators plan to evaluate these endpoints in a randomized, controlled setting against established hemodynamically-guided shock therapy.
Investigational measurements:
The investigators will perform the following new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements:
Patient characteristics:
- Sepsis-related Organ Failure Assessment (SOFA) score, daily
- APACHE II score, first 24 hours
- Simplified Acute Physiology (SAPS) II score, first 24 hours
Established parameters:
- Hemodynamic parameters (cardiac index [5], central venous pressure, blood pressure, heart rate, central/mixed venous oxygen saturation = ScvO2/venous oxygen saturation (SvO2), pulmonary capillary occlusion pressure (PAOP)
- Use of inotropic and vasoactive drugs (epinephrine, norepinephrine, milrinone, dobutamine, levosimendan)
- Laboratory parameters (lactate, sodium, potassium, blood sugar concentration and need for insulin therapy with respect to need for immunosuppressive therapy)
Parameters of renal function (creatinine, creatinine clearance, blood urea nitrogen, urine output, potassium, urinary protein, urinary sediment analysis, sodium excretion fraction, need for renal replacement therapy)
- Creatinine clearance after 24, 48, and 72 hours
- Urinary sediment analysis 72 hours
- Urinary protein screening after 72 hours
Fluid administration:
- Total amount of fluids (ml) administered
- Total amount of crystalloids (ml) administered after onset of shock symptoms
- Total amount of colloids (ml) administered
- Amount of red blood cell and plasma transfusion
- Amount of albumin infusion
Alternative parameters influenced by severity of capillary leakage and microcirculatory injury:
- Renal artery resistive index (Doppler analysis)
- Intra-abdominal pressure (bladder pressure management)
- Total body water (bio-impedance analysis): this is a commonly used method for assessment of body composition
- Microcirculatory blood flow (CytoCam incident dark-field illumination): "hand-held device (…), providing new means of directly visualizing the microcirculation and evaluating the effects of interventions on microcirculatory flow in easily accessible surfaces"
Outcome parameters:
- Acute kidney injury according to 'Kidney Disease: Improving Global Outcomes' (KDIGO) criteria
- Need for renal replacement therapy
- Length of intensive care stay
- Length of hospital stay
Safety: risks and benefits:
Since the investigators are only performing noninvasive measurements, additional to interventions, pharmacotherapy and measurements in shock patients, there will be no contributing risk by study enrolment. Since there will be a more precise way for guidance of fluid resuscitation in shock evoked by these study-specific measurements (bio-impedance analysis, doppler analysis, CytoCam incident darkfield illumination), study patients might even benefit from enrolment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- State of shock (any type) upon admittance to the ICU.
Exclusion Criteria:
- Age below 18 years
- Non-shock state
- Terminal state
- Pregnancy
- Jehovah's Witnesses
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Volume Resuscitation
We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
|
We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute kidney injury (KDIGO staging for severity of acute kidney injury ).
Time Frame: Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis
|
Change in renal function from baseline according to KDIGO staging
|
Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in lactate values (µmol/l)
Time Frame: Between 6 and 24 hours after admittance to the ICU and baseline (t1/t2 - t0)
|
Between 6 and 24 hours after admittance to the ICU and baseline (t1/t2 - t0)
|
|
|
Need for renal replacement therapy (KDIGO staging for severity of acute kidney injury)
Time Frame: Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis
|
Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis
|
|
|
Length of ICU stay
Time Frame: 1 month
|
If Patient stay exceeds one month, we will assess the data at intervals of one month
|
1 month
|
|
Length of hospital stay
Time Frame: 1 month
|
If Patient stay exceeds one month, we will assess the data at intervals of one month
|
1 month
|
|
Need for mechanical ventilation
Time Frame: During 27 hours
|
During 27 hours
|
|
|
In-hospital, 30-, and 90-day mortality
Time Frame: 0-90 days
|
0-90 days
|
Collaborators and Investigators
Investigators
- Study Chair: Martin Siegemund, MD, Deputy Chief Physician, Surgical Intensive Care Unit
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EKNZ 2015-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... and other collaboratorsCompletedWounds and Injuries | Hemorrhagic Shock | Traumatic ShockFrance
-
Biomedizinische Forschungs gmbHMedical University of ViennaCompletedSepsis | Toxic-Shock Syndrome
-
Haukeland University HospitalMinistry of Defence, NorwayCompletedHemorrhagic Shock | Hypovolemic ShockNorway
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletedTraumatic Haemorrhagic ShockUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Completed
-
Assiut UniversityUnknown
-
University of ManitobaCanadian Institutes of Health Research (CIHR); CancerCare ManitobaTerminatedSeptic Shock | Vasodilatory ShockCanada, United States, Brazil, Greece, India, Pakistan, Philippines
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center and other collaboratorsRecruiting
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHemorrhagic ShockUnited States
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletedHemorrhagic ShockUnited States
Clinical Trials on Measurement
-
University Hospital, Clermont-FerrandCompletedCoronary Artery Disease | Coronary Artery Bypass | Pulmonary Atelectasis | Anesthesia, General | HypovolemiaFrance
-
Ain Shams UniversityUnknown
-
Hasselt UniversityTRACE labs Ziekenhuis Oost-Limburg (ZOL)RecruitingBurnout, Psychological | FibromyalgiaBelgium
-
Hasselt UniversityTRACE labs Ziekenhuis Oost-Limburg (ZOL)Recruiting
-
Kutahya Health Sciences UniversityRecruiting
-
Medical University of GrazRecruitingDelirium | Critical IllnessAustria
-
Centre Hospitalier Universitaire Saint PierreMasimo Corporation; Centre Hospitalier Universitaire BrugmannCompletedOut-Of-Hospital Cardiac Arrest | Oxygen ToxicityBelgium
-
Southeast University, ChinaUnknownEndothelial Dysfunction | ARDS, Human | Mechanical Ventilation Pressure HighChina
-
Istanbul Medeniyet UniversityNot yet recruiting
-
Ankara City Hospital BilkentCompletedHypothermia | Orthopedic Disorder | Hip ArthropathyTurkey